Enzo Reports 11 Percent Decline in Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Tuesday that revenues for its fiscal second quarter dropped 11 percent year over year.

Total revenues for the three months ended Jan. 31 fell to $22.2 million from $25.0 million a year ago. By segment, clinical laboratory services shrank 6 percent to $13.3 million from $14.1 million, while product revenues slid 17 percent to $7.9 million from $9.5 million, and royalty and license fee revenues were down 23 percent to $1.0 million from $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.